List of articles with "Thousand Oaks"

IMDELLTRA® FDA Approval

IMDELLTRA® FDA Approval

Amgen Thousand Oaks SCLC IMDELLTRA
Amgen's Dividend Announcement

Amgen's Dividend Announcement

United States Dividend biotechnology Amgen Thousand Oaks
TEZSPIRE® Approval

TEZSPIRE® Approval

United States Amgen Thousand Oaks TEZSPIRE Allergy
Most Loved Workplaces

Most Loved Workplaces

United States Thousand Oaks Most Loved Workplaces Employee Satisfaction Lightfully Behavioral
Lindsey Carnett Keynotes

Lindsey Carnett Keynotes

USA Thousand Oaks California Lutheran University Marketing Maven Lindsey Carnett
AmgenNow Program

AmgenNow Program

USA Amgen Thousand Oaks Repatha AmgenNow
Repatha Trial Results

Repatha Trial Results

USA Amgen Thousand Oaks Repatha VESALIUS-CV
Amgen’s $650M Expansion

Amgen’s $650M Expansion

USA biopharmaceuticals Amgen Thousand Oaks USA manufacturing
Carnett's New Role

Carnett's New Role

United States Thousand Oaks American Cancer Society Relay For Life Lindsey Carnett
2025 Relay For Life

2025 Relay For Life

United States Thousand Oaks American Cancer Society Conejo Valley Relay For Life
Rocatinlimab Phase 3 Results

Rocatinlimab Phase 3 Results

USA Amgen Thousand Oaks Kyowa Kirin Rocatinlimab
Fitness Leadership Enhancement

Fitness Leadership Enhancement

USA Thousand Oaks 24 Hour Fitness ISSA Personal Trainers
Karen Hjerleid Joins Lightfully

Karen Hjerleid Joins Lightfully

United States mental health Thousand Oaks Lightfully Health Karen Hjerleid
Amgen's Major Investment

Amgen's Major Investment

United States Innovation Amgen Thousand Oaks Biopharmaceutical
Britt Freiden CSO

Britt Freiden CSO

United States mental health Thousand Oaks Lightfully Behavioral Health Britt Freiden
Repatha Approval Expanded

Repatha Approval Expanded

United States Amgen Thousand Oaks Repatha LDL Cholesterol
Visit Conejo Valley

Visit Conejo Valley

USA Thousand Oaks Agoura Hills Conejo Valley
Fantasy Camp for LA Youth

Fantasy Camp for LA Youth

United States Thousand Oaks 24 Hour Fitness Angel City FC LA Youth
Amgen Second Quarter 2025

Amgen Second Quarter 2025

USA Amgen Thousand Oaks Repatha TAVNEOS
Amgen's Q3 2025 Dividend

Amgen's Q3 2025 Dividend

United States Dividend biotechnology Amgen Thousand Oaks
Voyage Veterinary Advisors

Voyage Veterinary Advisors

USA Thousand Oaks Veterinary Advisors Practice Sales Transition Support
Amgen's Bemarituzumab Trial Results

Amgen's Bemarituzumab Trial Results

United States Amgen Thousand Oaks gastric cancer Bemarituzumab
Barry Sanders & Cholesterol

Barry Sanders & Cholesterol

USA Amgen Thousand Oaks Barry Sanders Cholesterol
IMDELLTRA® Breakthrough

IMDELLTRA® Breakthrough

United States Amgen Thousand Oaks small cell lung cancer IMDELLTRA®
GSD Expands Los Angeles

GSD Expands Los Angeles

United States Thousand Oaks Golden State Dermatology Dr. Peterson Pierre
IMDELLTRA® and SCLC

IMDELLTRA® and SCLC

USA Amgen Thousand Oaks SCLC IMDELLTRA
CAP-003 Data Release

CAP-003 Data Release

USA Thousand Oaks Parkinson's Capsida CAP-003
Latigo Biotherapeutics Funding

Latigo Biotherapeutics Funding

United States Pain Management Thousand Oaks Latigo Biotherapeutics Nav1.8 Inhibitor
Rocatinlimab Success

Rocatinlimab Success

USA Amgen Thousand Oaks Kyowa Kirin Rocatinlimab
Rocatinlimab Phase 3 Insights

Rocatinlimab Phase 3 Insights

USA Amgen Thousand Oaks Kyowa Kirin Rocatinlimab
Amgen Announces Dividend

Amgen Announces Dividend

USA Dividend Amgen Thousand Oaks Stock Market
Latigo's LTG-001 Fast Track Approval

Latigo's LTG-001 Fast Track Approval

United States FDA Approval Thousand Oaks Latigo Biotherapeutics LTG-001
Tezspire® Efficacy in CRSwNP

Tezspire® Efficacy in CRSwNP

United States Amgen Thousand Oaks Tezspire® CRSwNP
Amgen at Citi's Summit

Amgen at Citi's Summit

USA Innovation oncology Amgen Thousand Oaks
Amgen's 2024 Financial Growth

Amgen's 2024 Financial Growth

United States Amgen Thousand Oaks Repatha TEZSPIRE
Batteries Plus Support

Batteries Plus Support

USA Batteries Plus Thousand Oaks Emergency Preparedness Wildfire Support
BLINCYTO Approved

BLINCYTO Approved

USA Amgen Thousand Oaks BLINCYTO B-ALL
BLINCYTO Approval

BLINCYTO Approval

USA Amgen Thousand Oaks BLINCYTO B-ALL
BLINCYTO® Approval by EU

BLINCYTO® Approval by EU

USA Amgen Thousand Oaks BLINCYTO Acute Lymphoblastic Leukemia
BLINCYTO® Approved in EU

BLINCYTO® Approved in EU

USA Amgen Thousand Oaks Leukemia BLINCYTO
BLINCYTO® Approval

BLINCYTO® Approval

None Amgen Thousand Oaks Leukemia BLINCYTO
BLINCYTO® Approved

BLINCYTO® Approved

USA Amgen Thousand Oaks Leukemia BLINCYTO
Reviving LA Baseball

Reviving LA Baseball

United States Easton Thousand Oaks California Strong Rawlings
Dave & Buster's Opening

Dave & Buster's Opening

United States Dave & Buster's Thousand Oaks Gaming Entertainment
FDA Approves New Cancer Drug

FDA Approves New Cancer Drug

United States Thousand Oaks KRAS G12C Vectibix LUMAKRAS
Capsida and AbbVie Team Up

Capsida and AbbVie Team Up

USA Thousand Oaks Neurodegenerative Capsida AbbVie
New Doctors at DISC

New Doctors at DISC

USA Thousand Oaks DISC Surgery Center orthopedic care spine specialists
Amgen 2025 Dividend News

Amgen 2025 Dividend News

Dividend Amgen Thousand Oaks NASDAQ:AMGN
Capsida Gene Therapy

Capsida Gene Therapy

United States gene therapy Thousand Oaks Capsida STXBP1-DEE
Amgen at HealthCONx 2024

Amgen at HealthCONx 2024

USA biotechnology HealthCONx Amgen Thousand Oaks

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.